Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...

As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18 ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Third Harmonic Bio will halt non-THB335 research and cut 50% of its workforce while reviewing strategic options. Get real-time earnings alerts before the market moves and access expert analysis ...